ABSTRACT Background: Vitamin D insufficiency, which is prevalent in older individuals, is associated with bone and muscle weakness and falls. Objective: We examined the effects of a weekly dose of 8400 IU vitamin D 3 on postural stability, muscle strength, and safety. 
INTRODUCTION
Vitamin D insufficiency is prevalent in older individuals (1) (2) (3) (4) (5) . Among the major problems associated with inadequate vitamin D status are skeletal fragility and neuromuscular dysfunction (2) . Vitamin D deficiency leads to bone loss, largely because of secondary hyperparathyroidism aggravated by insufficient calcium intake, whereas adequate vitamin D intake enables normal bone mineralization, in part by stimulating increases in the absorption of calcium and phosphate from the intestine. The nuclear receptor for vitamin D was detected in many cell types, including enterocytes and muscle cells (2, 6, 7) . The abundance of vitamin D receptors in muscle declines in older women compared with younger women (8) , and hypovitaminosis D has been associated with poorer neuromuscular function in elderly individuals of either sex (9) .
Muscle weakness increases the likelihood of falls (10) . The association between low-vitamin D concentrations and falls has been shown in epidemiologic studies and randomized clinical trials and is supported by meta-analyses (10, 11) . In elderly individuals, especially those with osteoporosis, an elevated risk of falls leads to an elevated risk of fractures (11) , which are associated with excess morbidity and mortality (12, 13) .
The current randomized, double-blind, placebo-controlled trial was designed to assess whether a once-weekly treatment with 8400 IU vitamin D 3 would improve body postural stability and lower-extremity function in elderly people with low-vitamin D status (serum 25-hydroxyvitamin D [25(OH)D] concentrations 20 ng/mL) (2) . The primary endpoint, mediolateral sway with eyes open as assessed with the AccuSway PLUS platform (Advanced Medical Technology Inc, Watertown, MA), was shown to be significantly associated with recurrent falling in a subgroup of patients of the Longitudinal Aging Study Amsterdam (LASA) (14) . Stel et al (14) showed that increased mediolateral body sway was predictive of having more than one fall during a 12-mo period. They identified 0.46 cm as the value separating individuals who fell multiple times from individuals who did not fall or who had fallen once (odds ratio: 2.9; 95% CI: 1.3, 6.8) (14) .
In the current study, the dose of vitamin D 3 was selected-on the basis of the pharmacokinetic analysis of Barger-Lux et al (15) -so that patients would achieve serum 25(OH)D concentrations '20-33 ng/mL. This range of serum 25(OH)D concentrations corresponds to concentrations shown to be associated with improved neuromuscular function (16, 17) , lies well within vitamin D concentrations known to be safe (18, 19) , and is consistent with recommendations from the 2005 consensus on optimal vitamin D status (20) and from the World Health Organization (21) . During the 16 wk of treatment, physical performance, laboratory measures related to vitamin D status, and safety were monitored.
SUBJECTS AND METHODS

Patients
Patients were men and women aged 70 y who were vitamin D insufficient [serum 25(OH)D concentrations 20 but 6 ng/ mL]. All study participants were required to be ambulatory (able to walk 10 ft without a walking aid) and mentally competent [obtaining a score 24 on the Folstein's Mini-Mental State Examination (22) ]. If patients had serum 25(OH)D concentrations 6 but 9 ng/mL, they needed to have 24-h urine calcium concentrations 50 mg/d and bone-specific alkaline phosphatase concentrations not higher than the upper limit of normal to be eligible for the study. Exclusion criteria included primary hyperparathyroidism, active thyroid disease, impaired renal function, osteomalacia, neurologic impairment, peripheral neuropathy, myocardial infarction within 6 mo of screening, uncontrolled hypertension, postural hypotension, malabsorption syndrome, alcohol abuse (ie, .2 drinks/d), or cancer. Treatment with oral glucocorticoids, anabolic steroids, or a growth hormone within 12 mo of screening; treatment with .800 IU vitamin D/d or with active metabolites of vitamin D within 6 mo of screening; or treatment with any drug that might affect vitamin D metabolism or interfere with postural stability at screening were also reasons for exclusion. All patients signed an informed consent statement, and the protocol was approved by all institutional review boards [ After a 2-wk placebo run-in period, participants were randomly assigned 1:1 to receive a once-weekly dose of 8400 IU vitamin D 3 or a placebo. Participants were stratified (2:1) at randomization according to baseline serum 25(OH)D concentration (15 ng/ mL:.15 ng/mL). Patients were assigned a unique allocation number according to their appropriate stratification block. Investigators were blinded to serum 25(OH)D concentrations and to stratum definitions.
During the treatment period, participants received 3 tablets once per week containing a placebo or 2800 IU vitamin D 3 according to the treatment assignment. For those with a daily dietary calcium intake ,1000 mg (as assessed by a questionnaire at screening), daily calcium carbonate containing 500 mg elemental calcium was also prescribed.
Study participants were asked not to alter their diets or exercise regimens during the trial. Direct exposure to the sun was to be limited; participants agreed to apply sunscreen (sun protection factor 15) if exposure to direct sunlight for a period of time exceeding 15 min was anticipated. Patients also refrained from consumption of dietary supplements that contain .100 IU vitamin D per day, and they were to abstain from alcoholic beverages for 24 h before a clinic visit.
Assessments
Neuromuscular function
Postural stability was determined by measuring postural body sway, which is the corrective body movement resulting from the control of body position. The primary endpoint was mediolateral body sway, which was measured with eyes open with the AccuSway PLUS platform (Advanced Medical Technology Inc). This system analyzes input from strain gauges under a force platform and thereby calculates the center of pressure. The extent of the center-of-pressure movement is directly related to the individual's ability to maintain balance in an upright position. The balance tests were performed in patients with eyes open, standing on the force platform for 30 s with bare feet, and looking straight ahead. Four tests were performed at all study visits; the mean result was used for data analysis.
The lower-extremity performance was measured at all study visits by the SPPB (23, 24) , which included an assessment of standing balance, a gait speed test (ie, a timed 4-m walk), and timed rising from a chair and sitting without the use of arms for 5 repetitions. The SPPB was evaluated by using an ordered scale of 0-12 for combined measures of balance, gait speed, and ability to rise from and sit in a chair or as a continuous variable for the gait speed test separately (23) .
Laboratory values and adverse experiences
Chemical analysis was conducted at a central laboratory (Global Central Labs at Ppd, Highland Heights, KY). Serum parathyroid hormone (PTH) was detected with a DiaSorin Liaison chemiluminescence analyzer (DiaSorin, Stillwater, MN). Serum 25(OH)D concentrations were measured by reverse phase HPLC by using methodology previously described (25) . Adverse experiences (AEs) were recorded at each study visit and by the voluntary reporting of patients at any time during the study.
Statistical methods
The all-patients-treated population was used for efficacy analyses. Randomized participants who took at least one treatment dose were included in the all-patients-treated analyses, provided that the necessary baseline and at least one postrandomization data point were available. All statistical results were generated with a statistical program (SAS 8.2; SAS Institute Inc, Cary, NC).
A parametric analysis of covariance model with terms for baseline body sway, baseline vitamin D stratum, and treatment group was used to analyze data and estimate the within-and between-treatment differences for the primary endpoint of mediolateral body sway after treatment for 16 wk. A prespecified subgroup analysis on the basis of a baseline 25(OH)D concentration (15 or .15 ng/mL) and a post hoc subgroup analysis on the basis of baseline mediolateral sway with eyes open (0.46 or ,0.46 cm) were performed for the primary endpoint. For the analysis of urine calcium and serum PTH, a log transformation was used. The least-squares means were back transformed for the presentation of results.
The study was powered at 82% in the overall population and 80% in the low-baseline 25(OH)D stratum to detect betweentreatment differences in mediolateral sway with eyes open. The per protocol patient population, in which participants with important protocol deviations were excluded, was also evaluated for efficacy. Safety was assessed in all treated patients.
RESULTS
Men and women (n = 226) with a low vitamin D status [serum 25(OH)D concentrations 20 but 6 ng/mL] were randomly assigned to receive weekly vitamin D 3 8400 or a placebo for 16 wk. Participant inclusion and reasons for discontinuation in the trial are shown in Figure 1 . In general, the vitamin D and placebo groups were similar at baseline ( Table 1) . Participants were, on average, 78 y of age, 15% of participants used walking devices, 14% of participants resided in nursing homes, and the mean 25(OH)D concentration at baseline was 13.9 ng/mL. All patients who completed the trial were adherent to treatment, which was defined as taking 13 of the 16 total doses prescribed.
Neuromuscular function
Mediolateral sway
Mediolateral sway at 16 wk did not change from baseline in either placebo-treated or vitamin D 3 -treated participants, and there was no between-group difference (Figure 2A) . Although a between-group difference in the serum 25(OH)D concentration did occur at 8 wk and continued throughout the 16-wk trial (with a final 1.86-fold increase in vitamin D 3 -treated participants compared with a slight decrease in placebo-treated participants, P , 0.001; Figure 3) , no significant treatment differences in mediolateral sway were seen in either of the 2 prespecified subgroups on the basis of the baseline 25(OH)D concentration (15 or .15 ng/mL).
In a post hoc analysis, we examined mediolateral sway in subgroups on the basis of sway at baseline (Figure 2, B and C) . A baseline mediolateral sway of 0.46 cm was selected as the cutoff for subgroup analysis on the basis of work of Stel et al (14) . The post hoc analysis revealed a treatment difference in sway between patients with baseline sway 0.46 cm ( Figure 2B ). In this cohort (n = 31), mediolateral sway was reduced in the vitamin D 3 group compared with the placebo group (at week 16, the mean difference was 20.161 cm; P = 0.047). In the cohort with low baseline sway (,0.46 cm, n = 179), there was no difference between groups ( Figure 2C ).
SPPB
There was no significant difference in the change in SPPB scores between patients receiving vitamin D 3 and patients receiving the placebo ( Table 2) .
Laboratory assessments
Serum 25(OH)D concentrations rose (P , 0.001) in the vitamin D 3 -treated participants from '14 to '26 ng/mL during However, the analysis of interaction was limited by the small sample sizes in the subgroup analysis, and the larger changes in sway among only a few patients drove the interaction. the 16-wk study, whereas concentrations of vitamin D 3 in placebo-treated patients remained virtually unchanged ( Figure  3 ). At 16 wk, the mean difference between the 2 treatment groups was 13.0 ng/mL (P , 0.001). Analysis of the perprotocol population gave similar results.
For serum calcium, phosphate, creatinine, and albumin; 24-h urine creatinine; and creatinine clearance, no significant withintreatment percentage changes from baseline and no significant between-treatment differences were observed after 16 wk of treatment. An elevation in 24-h urine calcium for the 8400 IU vitamin D 3 group but not for the placebo group was observed. The between-group difference reached borderline significance ( Table 3) . Serum PTH decreased in 8400 IU vitamin D 3 -treated patients and increased in placebo-treated patients. The treatment difference was significant (Table 3) .
Safety
Clinical AEs occurred in 22% of the 226 randomized participants. The incidences of clinical, serious, and treatmentrelated AEs were similar in both treatment groups ( Table 4) . Eight participants (5 participants receiving the placebo and 3 participants receiving vitamin D 3 ) discontinued because of AEs. One death occurred after a myocardial infarction in a patient receiving vitamin D. There were no serious laboratory AEs. Incidences of hypercalcemia, hypercalciuria, or elevated creatinine did not differ between treatment groups, and no kidney stones were reported. Overall, the administration of a weekly dose of 8400 IU vitamin D 3 was well tolerated.
DISCUSSION
In this randomized, double-blind, placebo-controlled study in ambulatory, vitamin D-insufficient [serum 25(OH)D concentration 20 ng/mL] older adults, a once-weekly treatment with 8400 IU vitamin D 3 for 16 wk significantly increased serum 25(OH)D concentrations. Despite this, vitamin D treatment did not affect mediolateral body sway or alter neuromuscular function as measured by the SPPB. However, in post hoc analysis, among those participants with greater baseline mediolateral sway (0.46 cm), weekly 8400 IU vitamin D 3 reduced mediolateral sway. In the cohort with normal baseline sway, vitamin D 3 had no effect on mediolateral sway.
A once-weekly dose of 8400 IU vitamin D 3 increased the serum 25(OH)D concentration in participants by '12 ng/mL, an increment consistent with a prior report (15) . The study was conducted during the winter and spring, and there could have been a seasonal influence on 25(OH)D concentrations. However, the change in 25(OH)D concentrations in the placebo-treated group was only marginal, which indicates that the seasonal influence was not substantial. Treatment with 8400 IU vitamin D 3 also led to a reduction in serum PTH. The significant decrease in PTH (,5%) was smaller than might have been expected. We might have observed a larger decrease if the baseline 25(OH)D concentrations had been lower and the 25(OH)D concentrations had risen from '5 to 15 ng/mL instead of '15 to 25 ng/mL (26) . Finally, a trend toward increased urinary calcium excretion was observed with vitamin D 3 treatment, as could be expected in patients with a low vitamin D status (27) .
A once-weekly dose of 8400 IU vitamin D 3 was well tolerated. The incidence of hypercalcemia, hypercalciuria, or kidney stones did not differ between groups. Vitamin D 3 treatment was not associated with other laboratory, clinical, or serious AEs.
These results of neuromuscular function do not confirm the results of a number of studies (10, 16, (28) (29) (30) (31) (32) (33) (34) (35) that showed higher serum 25(OH)D concentrations to be associated with better physical performance. One possible reason for this discrepancy is that those with severe vitamin D deficiency (serum 25(OH)D concentration ,6 ng/mL) were excluded from the current study. Perhaps those with severe vitamin D deficiency experience the greatest physical performance benefit. In LASA, an epidemiologic study where patients with severe vitamin D deficiency were not excluded, the main improvement in physical performance occurred when serum 25(OH)D concentrations increased from 2 to 14 ng/mL (17) . Another possible explanation for the discrepancy is that so many patients in the current trial had low mediolateral sway at baseline, perhaps reflecting overall good health. In fact, mean baseline mediolateral sway in this study (0.33 cm) was similar to that of individuals who did not fall or who had fallen once in LASA using the same apparatus (0.34 cm), whereas the mean mediolateral sway of individuals who fell repeatedly in LASA was higher (0.43 cm) (14) . Furthermore, the baseline SPPB score of 9.1 in the current study was relatively high in the scale of 1-12, in which elderly patients with scores of 10-12 are considered the healthiest (24) . Thus, the results of the current study may represent a ceiling effect. Improvements in neuromuscular function as assessed by mediolateral sway may not occur above a ceiling or maximum level. In the current study, many patients were at or near this maximum level of neuromuscular function at baseline. In a post hoc subgroup analysis, the patients who were not near the ceiling level of neuromuscular function at baseline did experience an average improvement in mediolateral sway with treatment with 8400 IU vitamin D 3 . The subgroup analysis that was prespecified in the study protocol-change in sway between patients with lower 25(OH)D concentrations compared with patients with higher 25(OH)D concentrations-did not yield a significant difference. Several observations may explain this unexpected result: the number of patients with lower 25(OH)D concentrations may have been too small to detect a statistically significant difference between the 2 subgroups; the study population was one of overall good health; and the baseline sway, even in the patients with lower 25(OH)D concentrations, was quite low.
The main limitation of this study was that a substantial number of participants had mediolateral sway values at baseline that were consistent with participants who did not fall, suggesting that their balance as measured by sway was adequate. In these patients, there may have been little room for improvement of sway and physical performance with treatment. Another limitation of the trial was its small size. In our estimation, the primary endpoint did not provide a clear answer because of the unusually healthy condition of the elderly patients enrolled in this trial and perhaps to the low number of patients enrolled. Neuromuscular efficacy was only observed by post hoc analysis in a subset with greater mediolateral sway at baseline.
In conclusion, in the current investigation of elderly men and women, 16 wkoftreatment with8400IU vitamin D 3 onceweeklydid not alter mediolateral sway as measured with the AccuSway PLUS platform (Advanced Medical Technology Inc) or physical performance as measured by the SPPB. In the small subgroup of participants with elevated sway at baseline who were examined in a post hoc analysis, improvements in sway occurred with vitamin D 3 treatment compared with the placebo treatment. The weekly dose of 8400 IU vitamin D 3 , a dose well above currently recommended intakes (20, 21) , was well tolerated.
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